Dramatic upregulation of HRY has been noted in various cancer types, including breast cancer [60], colon cancer [46, 61, 62], glioma [63], head and neck squamous cell carcinoma [64], hepatocellular carcinoma [65], lung cancer [66], medulloblastoma [67], meningioma [68], NPC [51] and ovarian carcinoma [69]. This evidence concerns the gene HES1 and breast carcinoma.